Increased Risk of Atrial Fibrillation After Treatment for Differentiated Thyroid Carcinoma | Zendy

Esther N. Klein Hesselink | Zendy; Joop D. Lefrandt | Zendy; E. P. Schuurmans | Zendy; Johannes G. M. Burgerhof | Zendy; Bart Groen | Zendy; Ron T. Gansevoort | Zendy; Anouk N.A. van der HorstSchrivers | Zendy; Robin P. F. Dullaart | Zendy; Isabelle C. Van Gelder | Zendy; Adrienne H. Brouwers | Zendy; Michiel Rienstra | Zendy; Thera P. Links | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Increased Risk of Atrial Fibrillation After Treatment for Differentiated Thyroid Carcinoma

Author(s) -

Esther N. Klein Hesselink,

Joop D. Lefrandt,

E. P. Schuurmans,

Johannes G. M. Burgerhof,

Bart Groen,

Ron T. Gansevoort,

Anouk N.A. van der HorstSchrivers,

Robin P. F. Dullaart,

Isabelle C. Van Gelder,

Adrienne H. Brouwers,

Michiel Rienstra,

Thera P. Links

Publication year - 2015

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2015-2782

Subject(s) - medicine , atrial fibrillation , cumulative incidence , hazard ratio , confidence interval , proportional hazards model , thyroid carcinoma , incidence (geometry) , thyroid cancer , cumulative dose , cohort , cardiology , gastroenterology , endocrinology , thyroid , optics , physics

Patients with differentiated thyroid carcinoma (DTC) have a favorable prognosis after treatment with thyroidectomy, radioiodine, and TSH suppression. However, treatment is associated with long-term cardiovascular toxicity. The aim of this study was to evaluate whether there is an increased risk of atrial fibrillation (AF) in DTC patients and whether AF occurrence is related to DTC treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research